These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hedgehog Pathway Inhibition. Sekulic A; Von Hoff D Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418 [TBL] [Abstract][Full Text] [Related]
3. Correlations between the Sonic Hedgehog pathway and basal cell carcinoma. Lupi O Int J Dermatol; 2007 Nov; 46(11):1113-7. PubMed ID: 17988327 [TBL] [Abstract][Full Text] [Related]
4. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond. Mohan SV; Chang AL Semin Cutan Med Surg; 2014 Jun; 33(2):68-71. PubMed ID: 25085664 [TBL] [Abstract][Full Text] [Related]
5. Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas. Albert B; Hahn H Adv Exp Med Biol; 2014; 810():329-41. PubMed ID: 25207374 [TBL] [Abstract][Full Text] [Related]
6. [Not Available]. Basset-Seguin N Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683 [TBL] [Abstract][Full Text] [Related]
8. Hedgehog pathway inhibition and the race against tumor evolution. Atwood SX; Chang AL; Oro AE J Cell Biol; 2012 Oct; 199(2):193-7. PubMed ID: 23071148 [TBL] [Abstract][Full Text] [Related]
9. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. Skvara H; Kalthoff F; Meingassner JG; Wolff-Winiski B; Aschauer H; Kelleher JF; Wu X; Pan S; Mickel L; Schuster C; Stary G; Jalili A; David OJ; Emotte C; Antunes AM; Rose K; Decker J; Carlson I; Gardner H; Stuetz A; Bertolino AP; Stingl G; De Rie MA J Invest Dermatol; 2011 Aug; 131(8):1735-44. PubMed ID: 21430703 [TBL] [Abstract][Full Text] [Related]
10. Smoothened inhibitors in the treatment of advanced basal cell carcinomas. Kunstfeld R Curr Opin Oncol; 2014 Mar; 26(2):184-95. PubMed ID: 24469022 [TBL] [Abstract][Full Text] [Related]
11. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Danhof R; Lewis K; Brown M Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802 [TBL] [Abstract][Full Text] [Related]
12. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma. Tang JY Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S6-9. PubMed ID: 22177103 [TBL] [Abstract][Full Text] [Related]
13. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC). Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M Cells; 2022 Oct; 11(20):. PubMed ID: 36291078 [TBL] [Abstract][Full Text] [Related]
14. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Metcalfe C; de Sauvage FJ Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911 [TBL] [Abstract][Full Text] [Related]
15. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Sánchez-Danés A; Larsimont JC; Liagre M; Muñoz-Couselo E; Lapouge G; Brisebarre A; Dubois C; Suppa M; Sukumaran V; Del Marmol V; Tabernero J; Blanpain C Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799 [TBL] [Abstract][Full Text] [Related]
16. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Yauch RL; Dijkgraaf GJ; Alicke B; Januario T; Ahn CP; Holcomb T; Pujara K; Stinson J; Callahan CA; Tang T; Bazan JF; Kan Z; Seshagiri S; Hann CL; Gould SE; Low JA; Rudin CM; de Sauvage FJ Science; 2009 Oct; 326(5952):572-4. PubMed ID: 19726788 [TBL] [Abstract][Full Text] [Related]
17. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas. Piérard-Franchimont C; Hermanns-Lê T; Paquet P; Herfs M; Delvenne P; Piérard GE Future Oncol; 2015 Nov; 11(22):2997-3002. PubMed ID: 26437034 [TBL] [Abstract][Full Text] [Related]
18. Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiation. Uhmann A; Niemann H; Lammering B; Henkel C; Hess I; Nitzki F; Fritsch A; Prüfer N; Rosenberger A; Dullin C; Schraepler A; Reifenberger J; Schweyer S; Pietsch T; Strutz F; Schulz-Schaeffer W; Hahn H Mol Cancer Ther; 2011 Nov; 10(11):2179-88. PubMed ID: 21878656 [TBL] [Abstract][Full Text] [Related]